Glargine, 300 U/mL (Glar-300), had a favorable weight profile compared with degludec, 100 U/mL (Deg-100); degludec, 200 u/mL (Deg-200); thrice-weekly degludec (Deg-3TW); glargine, ... wrote. All articles from the July 13, 2018, ACP Diabetes Monthly
stage kidney disease, doubling of creatinine, or death from renal causes) (HR, 0.66; 95% CI, 0.53 to 0.81; P<0.001) with the drug. ... All articles from the May 10, 2019, ACP Diabetes Monthly Newsletter.
To update this recommendation, the USPSTF commissioned an evidence review that was published online April 14 by Annals of Internal Medicine and covered in the April 14 ACP Internist Weekly. ... All articles from the November 13, 2015, ACP Diabetes
All articles from the November 14, 2014, ACP Diabetes Monthly Newsletter.
Using electronic health records from 1 health system, researchers followed 726 patients (mean age, 45.2 years; 83.1% women) for 7 to 12 years after Roux-en-Y gastric bypass ... All articles from the September 16, 2016, ACP Diabetes Monthly Newsletter.
The observational case-control analysis used data from the United Kingdom Clinical Practice Research Datalink to find patients newly treated with tramadol or codeine for noncancer pain between 1998 and 2012. ... All articles from the January 9, 2015, ACP
The control group of 75 patients did not exercise. Intervention patients underwent 5 weekly sessions of low-amount, low-intensity (LALI) exercise; high-amount, low-intensity (HALI) exercise; or high-amount, ... All articles from the March 13, 2015, ACP
At 16 U.S. sites, researchers compared the adapted program (which included weekly in-person WW meetings, standard online tools, and coordinated telephone and email consultations with a certified diabetes educator) ... All articles from the November 11,
Expert panel recommends SGLT2 inhibitor or GLP-1 receptor agonist for patients with type 2 diabetes and CVD
pathway from the American College of Cardiology. ... All articles from the December 14, 2018, ACP Diabetes Monthly Newsletter.
The evidence-based guidance statement from ACP calls for personalized goals and an HbA1c target between 7% and 8% for most patients with type 2 diabetes. ... All articles from the March 9, 2018, ACP Diabetes Monthly Newsletter.